Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Eliapixant in Hepatic Impairment
NCT04454424Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2020
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of eliapixant in chronic cough, overactive bladder (OAB), endometriosis and 1 more (5 arms), sponsored by Bayer. Primary endpoints: Unbound Area Under the Curve at Day 1 and Unbound Maximum Plasma Concentration at Day 1. Started Jul 2020; status: completed.
02
Drugs
eliapixant
03
Conditions
chronic coughoveractive bladder (OAB)endometriosisdiabetic neuropathy
Beyond the preview
Go deeper on NCT04454424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454424.